An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
Researchers sought to determine whether late mortality rates are affected by exposure to a BCR-ABL TKI prior to BMT in patients with CML who survive at least 2 years posttransplantation.
Increased familial relative risks for the same tumor type for most hematological malignancies.
Further studies needed to look at relevance outside of the transplant-eligible population.
An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.